Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG1940 and CG8711 versus docetaxel + prednisone in metastatic hormone-refractory prostate cancer
2005-002738-36Phase 3Terminated
- Sponsor
- Cell Genesys
- Start
- Jul 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing CG1940 + CG8711 with Docetaxel + prednisone (2 arms). Primary endpoint: Overall survival. Started Jul 2005; status: terminated.
02
Drugs
autologous RCC vaccinedocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-002738-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002738-36.